Avacta Group has announced that the principal patent protecting the Affimer technology had been accepted for grant in China.

Avacta said that on issuance, this patent would extend coverage of Avacta's intellectual property into another potentially large market for the company.

It said that considering the therapeutic applications of Affimers alone, China now accounted for more than one fifth of the global therapeutic antibody market. It said counterparts to this patent had already been granted in the US, Europe and Japan.

Group chief executive Dr Alastair Smith said:"The grant of a robust patent to cover the core Affimer intellectual property in China adds further strength to our global intellectual property position.

"We continue to develop the core technology and I look forward to updating the market regarding further expansion of our Affimer intellectual property estate in due course."

At 9:53am: (LON:AVCT) Avacta Group PLC share price was +4.5p at 90p